Kenvue Inc. (NYSE:KVUE) Shares Sold by Wells Fargo & Company MN

Wells Fargo & Company MN trimmed its position in Kenvue Inc. (NYSE:KVUE) by 10.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 4,380,382 shares of the company’s stock after selling 495,826 shares during the period. Wells Fargo & Company MN’s holdings in Kenvue were worth $93,521,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of KVUE. Vanguard Group Inc. increased its position in shares of Kenvue by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company’s stock worth $4,665,908,000 after purchasing an additional 1,636,741 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Kenvue by 12.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company’s stock valued at $2,085,070,000 after acquiring an additional 10,682,003 shares during the period. Geode Capital Management LLC raised its stake in shares of Kenvue by 3.1% in the 4th quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company’s stock valued at $980,989,000 after acquiring an additional 1,391,854 shares during the period. Franklin Resources Inc. boosted its position in shares of Kenvue by 61.5% during the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company’s stock worth $912,059,000 after purchasing an additional 16,269,721 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Kenvue by 2.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 24,972,777 shares of the company’s stock worth $533,169,000 after purchasing an additional 561,570 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Trading Down 2.6 %

Shares of NYSE:KVUE opened at $21.76 on Tuesday. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The company’s 50 day moving average is $22.60 and its two-hundred day moving average is $22.45. The company has a market cap of $41.58 billion, a PE ratio of 41.05, a P/E/G ratio of 2.62 and a beta of 1.02. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were issued a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.77%. The ex-dividend date was Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is 154.72%.

Analyst Upgrades and Downgrades

A number of research analysts have commented on KVUE shares. Evercore ISI assumed coverage on Kenvue in a research note on Monday, March 24th. They set an “in-line” rating and a $25.00 price target on the stock. Royal Bank of Canada reissued a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Citigroup dropped their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and reduced their price target for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Finally, Piper Sandler upped their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research note on Monday, February 24th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $24.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.